Zepbound vs Wegovy: The Two Leading Weight-Loss Drugs Compared

When the two most popular weight-loss injections were finally tested head-to-head, Zepbound came out ahead: in the SURMOUNT-5 trial, tirzepatide (Zepbound) produced 20.2% weight loss versus 13.7% for semaglutide (Wegovy). Both are FDA approved, highly effective, and widely used, but Zepbound’s dual mechanism gives it a measurable edge on weight loss. That said, Wegovy has its own strengths, including a broader set of approved uses. Here’s how the two compare directly.

The Key Mechanistic Difference

The reason for the gap comes down to how each drug works. Wegovy (semaglutide) activates a single receptor, GLP-1, to reduce appetite. Zepbound (tirzepatide) activates two, GLP-1 and GIP, adding a second hormone that enhances the effect. That extra mechanism is what appears to drive Zepbound’s greater weight loss. Both are once-weekly injections, so the difference is in the drug, not the delivery.

Head to Head

The Head-to-Head Data

This is one of the rare cases with a direct comparison. In the SURMOUNT-5 trial, published in the New England Journal of Medicine in 2025, adults with obesity took either drug at its maximum dose for 72 weeks. Tirzepatide produced 20.2% average weight loss versus 13.7% for semaglutide, roughly 47% more weight lost. Tirzepatide users were also more likely to hit milestones like 20% and 25% weight loss. Interestingly, gastrointestinal side effects leading to discontinuation were somewhat less common with tirzepatide (2.7%) than semaglutide (5.6%). So on both efficacy and this measure of tolerability, Zepbound had the advantage in this trial.

Where Wegovy Has the Edge

Weight loss isn’t the whole story. Wegovy has a broader set of FDA-approved uses: beyond obesity, it’s approved to reduce cardiovascular risk (heart attack and stroke) in people with established heart disease, and more recently for MASH, a serious fatty liver disease. Zepbound, meanwhile, is approved for obstructive sleep apnea in addition to obesity. So the “better” drug partly depends on your health picture. Consider a hypothetical patient with obesity and established heart disease: Wegovy’s cardiovascular indication might make it the more fitting choice, even though Zepbound produces more weight loss on average.

How to Choose

If maximum weight loss is your main goal, Zepbound has the stronger data. If you have a condition that one drug is specifically approved to treat (heart disease for Wegovy, sleep apnea for Zepbound), that may tip the decision. Cost, insurance coverage, and how you tolerate each also matter, which is why this is a conversation to have with a provider rather than a fixed answer.

What This Means for You Right Now

Both drugs are available, and both are among the brand options TrimRx offers, alongside compounded semaglutide and compounded tirzepatide. That means you can access either the more powerful dual agonist or the semaglutide option through a provider who can help you decide based on your goals and health profile.

Frequently Asked Questions

Is Zepbound or Wegovy more effective for weight loss?

Zepbound (tirzepatide) is more effective on average. In the head-to-head SURMOUNT-5 trial, it produced 20.2% weight loss versus 13.7% for Wegovy (semaglutide), thanks to its dual GLP-1/GIP mechanism.

Why might someone choose Wegovy over Zepbound?

Wegovy has broader approved uses, including cardiovascular risk reduction and MASH (liver disease), so it may fit better for people with those conditions. Insurance coverage, tolerability, and personal preference also factor in.

Are both available now?

Yes. Both Zepbound and Wegovy are FDA approved and available. TrimRx offers both as brand options, along with compounded semaglutide and tirzepatide.

To find which fits you, you can check what you’re eligible for with a licensed provider.

This information is for educational purposes and is not medical advice. Consult a healthcare provider before starting any medication. Individual results may vary.